Thursday, February 23, 2017

Lunch Workshop - Tolerance Shark Tank

Moderators:
Anthony M. Jevnikar, MD, London Health Sciences Center
James S. Allan, MD, MBA, Massachusetts General Hospital

Treg Studies in Clinical Transplant - Your Safest Investment
Sandy Feng, MD, PhD, University of California, San Francisco

Who Needs T Regs if You have Facilitator Cells and Chimerism?
Joseph R. Leventhal, MD, PhD, Northwestern University Medical School

Tregs Are Not the Only ONE to Study
James Markmann, MD, PhD, Massachusetts General Hospital

Welcome Remarks

Continuing education is not offered for this session.

Session 1:  Time to Refocus from Early to Late Outcomes

Moderators:
Alexander Wiseman, MD, University of Colorado of Denver HSC
Roy D. Bloom, MD, Hospital of the University of Pennsylvania

Observations from DEKAF
Arthur J. Matas, MD, University of Minnesota

Can We Predict the Future and Change it?: Gocar
Philip O’Connell, PhD, FRACP, University of Sydney at Westmead Hospital

Novel Strategies to Improve Adherence in Transplant Recipients
Christopher D. Blosser, MD, University of Washington

Treatment of Chronic Antibody Mediated Rejection
Robert A. Montgomery, MD, D.Phil, FACS, NYU Lagone Medical Center

Welcome Reception and Poster Presentations
Location:  Frank Lloyd Wright Salon G

Session 2:  Challenges to Therapeutic Innovation in Transplant: Multiple Perspectives

Moderators:
Roslyn B. Mannon, MD, University of Alabama, Birmingham
Andrew B. Adams, MD, PhD, Emory University School of Medicine

Investigator's Perspective
Chris Larsen, MD, PhD, Emory University

Industry’s Perspective
Herwig-Ulf Meier-Kriesche, MD, Bristol-Myers Squibb

The Perspective of a Successful Outsider Path Forward
Joan Merrill, MD, Oklahoma Medical Research Foundation

Friday, February 24, 2017

7:15 AM - 8:15 AM

Satellite Symposium*
Presented by One Lambda Inc., A Thermo Fisher Scientific Brand
Location:  Frank Lloyd Wright Salon A

Precision Medicine in Transplantation: Reclassifying Graft Rejection and Injury with the Molecular Microscope and Integrative Diagnostics

Philip F. Halloran, MD, PhD, Alberta Transplant Applied Genomics Centre, Edmonton, Canada
Alexandre Loupy, MD, PhD, Necker Hospital, Paris, France
Carmen LeFaucheur, MD, Saint Louis Hospital, Paris France
Gaurav Gupta, MD, Virginia Commonwealth University, Richmond, VA

(*This is not an official function of the CEOT Meeting and is not endorsed by the AST. Breakfast provided by AST.)

Continuing education is not offered for this session.

Session 3 (CHOOSE ONE OF THREE OPTIONS)

Option 1 - No Transplantable Organ Left Behind

Moderators:
Richard N. Formica, Jr., MD, Yale University School of Medicine
Nicole Turgeon, MD, Emory University

Waste not Want Not: Analysis of Discarded Organs
Darren Stewart, M.S., United Network for Organ Sharing

New SRTR Metrics for Organ Acceptance
Jon Snyder, PhD, Chronic Disease Research Group

What Is the Risk in a PHS Increased Risk Kidney and How Do We Safely Use Them?
Michael G. Ison, MD, MS, Northwestern University

Who Gets the Kidney at Risk for Discard: Decisions Under Pressure
Amit K. Mathur, MD, MS, Mayo Clinic Scottsdale

Option 2 - Approach to the Sensitized Patient Awaiting Heart Transplant

Moderators:
Howard Eisen, MD Drexel University
Patricia Campbell, University of Alberta

Detection and Monitoring of Antibodies Pre-Heart Transplantation
Elaine Reed, PhD, David Geffen School of Medicine at UCLA

Outcomes of Pre Transplant Antibodies: Non-VAD and VAD
Jon Kobashigawa, MD, Cedars-Sinai Heart Institute

Should Sensitized Patients Have Allocation Priority?
Howard Eisen, MD, Drexel University

Managing Sensitized Patients Pre-Heart Transplantation
Patricia Chang, MD, University of North Carolina

Debate: Pre-Heart Transplant Conundrum: Desensitization Vs. Transplanting Against a Positive Flow Crossmatch
Pro Desensitization
Jignesh Patel, MD, Cedars-Sinai Heart Institute

Pro Transplanting Against a Positive Flow Crossmatch
Monica Colvin, MD, University of Michigan

Option 3 - The Conundrum of Circulating Antibodies in Patients Awaiting Lung Transplant

Moderators:
Martin Zamora, MD, University of Colorado
Kathryn Tinckam, MD, University of Toronto

Strategies for the Assessment of Sensitization in Candidates for Lung Transplantation
Dolly Tyan, PhD, Stanford University

Should the Presence of DSA Influence Recipient Selection in the Setting of Lung Transplantation? 
Hilary Goldberg, MD, Brigham and Women's Hospital

Complement Fixation and Risk Stratification in the Sensitized Lung Transplant Candidate
Adriana Zeevi, MD, University of Pittsburgh

Managing Sensitized Patients Pre-Lung Transplantation
Deborah Levine, MD, University of Texas

Debate: Pre-Lung Transplant Conundrum: Desensitization Vs. Transplanting Against a Positive Flow Crossmatch

Laurie Snyder, MD, Duke University - Pro Desensitization
Ramsey Hachem, MD, Washington University - Pro Transplanting Against a Positive Flow Crossmatch

Panel Discussion

Session 4 - AM Keynote Address

Historical Perspectives on the Failure to Enact the Immunosuppression Bill and Why this Goal Remains Important

Moderators:
Anil Chandraker, MD, Brigham & Women's Hospital
Dianne B. McKay, MD, University of California San Diego

Historical Perspectives
Robert S. Gaston, MD, University of Alabama @ Birmingham

Plan Moving Forward
Congressman Michael Burgess, M.D., (R-TX), Chairman of the U.S. House of Representatives’ Energy & Commerce Subcommittee on Health will discuss organ transplant patient public policy in the past, present and future, including the Comprehensive Immunosuppressive Drug Coverage for Kidney Patients Act.

Satellite Symposium*
Presented by Sanofi Genzyme
Location:  Frank Lloyd Wright Salon A

A Critical Appraisal of Induction Therapy in Kidney Transplantation

Topic 1: Induction in 2017:  Who Receives It and Who Needs It?
Alex Wiseman, MD, University of Colorado of Denver HSC

Topic 2: Induction With Depleting Agents:  What Are the Anticipated and Actual Benefits?
Bruce Kaplan, MD, Mayo Clinic

Topic 3: Depleting Induction and Steroid Avoidance:  Strategies and Benefits
E. Steven Woodle, MD

(*This is not an official function of the CEOT Meeting and is not endorsed by the AST. Lunch provided by AST.)

Continuing education is not offered for this session.

Session 5  (CHOOSE ONE OF THREE OPTIONS)

Option 1 - Recipient Candidacy: Do the Right Thing!

Moderators:
Robert S. Gaston, MD, University of Alabama @ Birmingham
Thomas Pearson, MD, DPhil, Emory University, Emory Transplant Center

Saying No, When Is It Necessary?
John Gill, MD, MS, Providence Health Care

Approaches to Transplant the High- Risk Recipients
Alexander Wiseman, MD, University of Colorado of Denver HSC

Prehabilitation- Training the Frail
Christopher Sonnenday, MD, MHS, University of Michigan Health System

Which Hat Am I wearing: Public Steward or Patient Advocate?
Timothy Caufield, BSc, LL.B., LL.M, University of Alberta

Option 2 - Post‐Heart Antibodies: What To Do?

Moderators:
Anat Tambur, DMD/PH, Northwestern University
Jon Kobashigawa, MD, Cedars-Sinai Heart Institute

Antibodies as a Marker for Poor Outcome Post-Heart Transplantation
Monica Colvin, MD, University of Michigan

Prevention of Antibody Development Post-Transplantation: Results from CTOT-11 Trial
Randy Starling, MD, Cleveland Clinic

Prevention of Complement Activation and Antibody Development: Results from the Duet Trial
Jignesh Patel, MD, PhD, Cedars-Sinai Heart Institute

Treatment of Detected Antibodies
Sean Pinney, MD,Icahn School of Medicine at Mt. Sinai

Non-HLA Antibodies Post-Heart Transplantation
Annette Jackson, PhD, Johns Hopkins

Post Heart-Transplant Conundrum: Do All Post HTx DSA Require Treatment? What About HLA Abs?
Adriana Zeevi, MD University of Pittsburgh

Option 3 - The Challenges of Post-Lung Transplant Antibodies

Moderators:
Laurie Snyder, MD, Duke University
Adriana Zeevi, MD, University of Pittsburgh
Sangeeta Bhorade, MD, Northwestern University

Antibodies as a Marker for Poor Outcome in Lung Transplantation
Deborah Levine, MD, University of Texas, San Antonio

Prevention of Antibody Development Post-Lung Transplantation
Martin Zamora, MD, University of Colorado

Non-HLA Antibodies (K-Alpha 1 Tubulin, Collagen V)
Nancy Reinsmoen, PhD, Cedars-Sinai 

Treatment of Detected Antibodies in Lung Transplantation
Ramsey Hachem, MD, Washington University in St. Louis

Connection of Circulating Antibodies to Pathology AMR on Lung Biopsy
Gerald Berry,MD, Stanford University

Post-Lung Transplant Conundrum: Do All Post Lung Transplant DSA Require Treatment?
Kathryn Tinckam, MD, University of Toronto

PM Keynote 

The Honorable Kevin Yoder, United States House of Representatives

Continuing education is not offered for this session.

Saturday, February 25, 2017

Session 6  (CHOOSE ONE OF THREE OPTIONS)

Option 1 - Transplant Value- How to Survive the Next Decade

Moderators:
Kenneth A. Newell, MD, PhD, Emory University School of Medicine
John Gill, MD, MS, Providence Health Care

Big Picture Healthcare Value/Reform in the US
John Sedor, MD, Metrohealth Medical Center

A Journey Towards Value
Darrell A. Campbell, Jr., MD, University of Michigan

Value the Private Payor Perspective
Jon Friedman, MD, Optum Health Complex Medical Conditions

Value the Public Payor Perspective
Daniel Schwartz, MD, MBA, CMS, U.S. Dept. of Health & Human Services

Option 2 - Case Studies in Heart Transplantation: Challenges in Treatment

Moderators:
Patricia Chang, MD, University of North Carolina
Jignesh Patel, MD, PhD,Cedars-Sinai

Pre-Transplant Treatment of the Sensitized Patient 
Sean Pinney, MD, Mount Sinai
Sumeet Mitter,MD, Northwestern 

Sensitization in the VAD Patient Awaiting Transplant:  When to Ignore and When to Treat
Annette Jackson, PhD Johns Hopkins
Tolulope Adesiyun, MD, Johns Hopkins

Does Persistence Pay Off?  Treatment of Recurrent AMR Acutely and Longitundinally
Randall Starling, MD, Cleveland Clinic
Paulino Alvarex, Cleveland Clinic

An Immune System Never Forgets:  Treatment of Delayed Hyperacute Rejection Post Transplant
Monica Colvin, MD, University of Michigan
Nicholas Furiasse, MD, Cedars Sinai

A Case of Graft Dysfunction:  Are Donor Specific Antibodies Bystanders or Instigators?
Francisco Arabia, MD,Cedars Sinai
Kevin Koomalsingh, MD, Cedars Sinai

Panel Discussion

Option 3 - Case Studies in Lung Transplantation: Practical Scenarios

Moderators: Deborah Levine, MD, University of Texas
Sangeeta Bhorade, MD Northwestern University

Post Transplant Treatment fo DSA With & Without Lung Dysfunction
Martin Zamora, MD, University of Colorado
Aarya Kafi, MD, Cedars Sinai

Severe PAH with Cardiogenic Shock: Is Heart/Lung Transplant the Best Option?
Rajeev Saggar, MD, Banner - University Medical Center Phoenix
Samir Sultan, DO, Banner Health

Supporting the Decompensated PH Patient Awaiting Lung Transplant
Jeremy Feldman, MD, Arizona Pulmonary Specialists
Ishna Poojary, MD, College of Medicine Tuscon Arizona

Acute AMR After Lung Transplantation 
Ramsey Hachem, MD, Washington University
Hrishikesh Kulkarni, MD, Washington University

Highly Sensitized Patient Awaiting Lung Transplant
Laurie Snyder, MD, Duke University
Lorenzo Zaffiri, MD, Duke University

Panel Discussion

Break

Session 7: Post - Transplant Infections:  Jeopardizing Long-Term Success

Moderators:
Emily A. Blumberg, MD, Hospital of the University of Pennsylvania

The Impact of Infections: Aspergillus to Zika
Emily Blumberg, MD, Hospital of the University of Pennsylvania

The Microbiome: Implications on Graft Survival
Jay A. Fishman, MD, Massachusetts General Hospital Transplant Center

T-Cell Therapies:  Promise and Practice
Susan E. Prockop, MD, Memorial Sloan Kettering Hospital

Lunch Workshop
Session 8:  Hepatitis C- Death of an Old Foe

Moderators:
Josh Levitsky, MD, MS, Northwestern U Feinberg School of Medicine
Richard N. Formica, Jr., MD, Yale University School of Medicine

HCV Consensus Conference Summary
Josh Levitsky, MD, MS, Northwestern U Feinberg School of Medicine
Richard N. Formica, Jr., MD, Yale University School of Medicine

Treatment of HCV Pre vs Post- transplant
Roy D. Bloom, MD, Hospital of the University of Pennsylvania

HCV + donors to HCV – Recipients
David Goldberg, MD, MSCE, University of Pennsylvania

Session 9: Biomarkers and Personalized Medicine: Why Can’t I Order It?

Moderators:
Ronald G. Gill, PhD, University of Colorado - Denver
Jon Kobashigawa, MD, Cedars Sinai Heart Institute

Surrogates: Why Do We Need Them and Why Haven’t We Developed Them?
Jesse Schold, PhD, M.Stat, M.Ed., Cleveland Clinic Foundation

Molecular Biomarkers - Why are There so Many Biomarkers to Predict Medicine and None are Used Clinically?
Philip F. Halloran, MD, PhD, Alberta Transplant Applied Genomics Centre, Edmonton, Canada

Surrogates as Clinical Endpoint and for Enrichment in Trials
Alexander Loupy, MD, PhD, Necker Hospital Paris

Break

Session 10: Donor Specific Antibody: Should We Avoid or Confront?

Moderators:
Peter Nickerson, MD, University of Manitoba Canadian Blood Services
Sharon M. Bartosh, MD, University of Wisconsin

Understanding Risks and Consequences
Kathryn J. Tinckam, MD, MMSc, FRCPC, University Health Network

Finding the Best Match: Looking to the Epitopes
Anat R. Tambur, DMB, PhD, Northwestern University

Increased Matching the Impact on Equity
Howard M. Gebel, PhD, Emory University Hospital
Robert A. Bray, PhD, Emory University Hospital

Closing

Anil Chandraker, MD, Brigham & Women’s Hospital
Kenneth A. Newell, MD, PhD, Emory University School of Medicine

Continuing education is not offered for this session.

Poolside Reception
Cabana Club, Paradise Pool